Enliven Therapeutics Inc (NASDAQ:ELVN)’s 12-Month Price Target Currently Stands At 40
In last trading session, Enliven Therapeutics Inc (NASDAQ:ELVN) saw 0.32 million shares changing hands with its beta currently measuring 1.02. Company’s recent per share price